Induction of Protection against Porcine Cysticercosis by Vaccination with Recombinant Oncosphere Antigens-Reference-Cited by-同舟云学术

Induction of Protection against Porcine Cysticercosis by Vaccination with Recombinant Oncosphere Antigens

Published:2004-09 Issue:9 Volume:72 Page:5292-5297
ISSN:0019-9567
Container-title:Infection and Immunity
language:en
Short-container-title:Infect Immun

Author:

Flisser Ana¹²,Gauci Charles G.³,Zoli André⁴,Martinez-Ocaña Joel¹,Garza-Rodriguez Adriana¹,Dominguez-Alpizar Jose Luis⁵,Maravilla Pablo¹,Rodriguez-Canul Rossana⁶,Avila Guillermina²,Aguilar-Vega Laura²,Kyngdon Craig³,Geerts Stanny⁷,Lightowlers Marshall W.³

Affiliation:

1. Direccion de Investigación, Hospital General “Dr. Manuel Gea Gonzalez,” SSA

2. Departamento de Microbiologia y Parasitologia, Facultad de Medicina, UNAM, Mexico DF

3. Veterinary Clinical Centre, The University of Melbourne, Werribee, Victoria, Australia

4. Taeniasis-Cysticercosis Project, Department of Animal Production, Faculty of Agriculture, University of Dschang, Dschang, Cameroon

5. Facultad de Medicina Veterinaria

6. CINVESTAV, Merida, Yucatan, Mexico

7. Prins Leopold Instituut voor Tropische Geneeskunde, Antwerp, Belgium

Abstract

ABSTRACT Two recombinant Taenia solium oncosphere antigens, designated TSOL18 and TSOL45-1A, were investigated as vaccines to prevent transmission of the zoonotic disease cysticercosis through pigs. Both antigens were effective in inducing very high levels of protection (up to 100%) in three independent vaccine trials in pigs against experimental challenge infection with T. solium eggs, which were undertaken in Mexico and Cameroon. This is the highest level of protection that has been achieved against T. solium infection in pigs by vaccination with a defined antigen. TSOL18 and TSOL45-1A provide the basis for development of a highly effective practical vaccine that could assist in the control and, potentially, the eradication of human neurocysticercosis.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Immunology,Microbiology,Parasitology

Link

https://journals.asm.org/doi/pdf/10.1128/IAI.72.9.5292-5297.2004

Reference39 articles.

1. Bogh, H. O., M. D. Rickard, and M. W. Lightowlers. 1988. Studies on stage-specific immunity against Taenia taeniaeformis metacestodes in mice. Parasite Immunol.10:255-264.

2. Cai, X., Z. Chai, Z. Jing, P. Wang, X. Luo, J. Chen, Y. Dou, S. Feng, C. Su, and J. Jin. 2001. Studies on the development of DNA vaccine against Cysticercus cellulosae infection and its efficacy. Southeast Asian J. Trop. Med. Public Health32(Suppl. 2):105-110.

3. Chow, C., C. G. Gauci, A. F. Cowman, and M. W. Lightowlers. 2004. Echinococcus granulosus: oncosphere-specific transcription of genes encoding a host-protective antigen. Exp. Parasitol.6:183-186.

4. Dalton, J. P., and G. Mulcahy. 2001. Parasite vaccines—a reality? Vet. Parasitol.98:149-167.

5. Dempster, R. P., C. M. Robinson, and G. B. Harrison. 1996. Parasite vaccine development: large-scale recovery of immunogenic Taenia ovis fusion protein GST-45W(B/X) from Escherichia coli inclusion bodies. Parasitol. Res.82:291-296.

Cited by 146 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurocysticercosis and the Central Nervous System: Advancements in Diagnosis, Treatment, and Future Prospects;Intestinal Parasites - New Developments in Diagnosis, Treatment, Prevention and Future Directions [Working Title];2024-06-10

2. Characterisation of protective vaccine antigens from the thiol-containing components of excretory/secretory material of Ostertagia ostertagi;Veterinary Parasitology;2024-06

3. Development and evaluation of time-resolved rapid immunofluorescence test for detection of TSOL18 specific antibody in porcine cysticercosis infections;BMC Veterinary Research;2024-05-08

4. Characterisation of protective vaccine antigens from the thiol-containing components of excretory/secretory material ofOstertagia ostertagi;2023-12-08

5. The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections;Clinical Microbiology Reviews;2023-03-23